Long-acting injections

Abstract

Insulin was discovered in 1921, and soon insulin extracted from bovine pancreas was tested on humans. After many processes, a genetically engineered human insulin preparation was launched in 1983. In addition, insulin analogs have been in use since 1996 to approximate physiological insulin secretion. At present, five types of ultra rapid-acting insulin as bolus insulin and five types of basal insulin are available. In particular, the latter formulation, which acts for 24 hours with a once-daily injection, is called a long-acting dissolved insulin. On the other hand, GLP-1 receptor agonists have been used since 2005, and a once-weekly formulation was approved in 2012. Currently, three different once-weekly formulations are available. In addition, combination injections of a long-acting dissolved insulin and a GLP-1 receptor agonist have been introduced.In this session, I will summarize the characteristics of each injectable drug and introduce the target patient population and treatment methods.